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Cardiac allografts induce host immune responses that lead to
endomyocardial tissue injury and progressive graft dysfunction.
Inﬂammatory cell inﬁltration and myocyte damage characterize
acute cellular rejection (ACR) that presents episodically in either
a subclinical or symptom-associated manner. Sampling of the en-
domyocardium by transvenous biopsy enables pathologic grading
using light microscopic criteria to distinguish severity based on
the focality or diffuseness of inﬂammation and associated myocyte
injury.MonitoringforACRutilizesendomyocardialbiopsyincon-
junction with history and physical examination and assessment of
allograft function by echocardiography. However, procedural and
interpretive issues limit the diagnostic certainty provided by en-
domyocardial biopsy. The dynamic proﬁling of genes expressed
by peripheral blood mononuclear cells (PBMCs) enables quanti-
tative assessments of intracellular mRNA whose levels ﬂuctuate
during systemic alloimmune responses. Gene expression proﬁling
ofPBMCsusingamulti-geneACRclassiﬁerenablestheAlloMap  R
molecular expression test to distinguish moderate to severe ACR
(p = 0.0018) in heart transplant patients. The AlloMap test pro-
vides molecular insights into a patient’s risk for ACR by distilling
theaggregateexpressionlevelsofitsinformativegenesintoasingle
score on a scale of 0 to 40. The selection of a score as a threshold
valueforclinicaldecision-makingisbasedonitsassociatednegative
predictive value (NPV), which ranges from 98 to 99% for values in
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threepost-transplantperiods:>2to≤6months,>6to≤12months,
and >12 months. Scores below the threshold value rule out ACR,
while those above suggest increased ACR risk. Incorporating the
AlloMaptestintoimmunomonitoringprotocolsprovidesanoppor-
tunity for clinicians to enhance patient care and to deﬁne its role
in immunodiagnostic strategies to optimize the clinical outcomes
of heart transplant recipients. This summary highlights the con-
cepts presented in an invited presentation at a conference focused
onImmunodiagnosticsandImmunomonitoring:FromResearchto
Clinic, in San Diego, CA on November 7, 2006.
Keywords acute cellular rejection, cardiac allografts, gene expres-
sion proﬁling
INTRODUCTION
Clinicianscaringforcardiactransplantpatientsmustbalance
the risks and beneﬁts of drug regimens designed to suppress im-
mune responses to the engrafted heart, while also recognizing
that acute and chronic forms of rejection may still occur despite
good compliance with complex therapies. Heart transplant pa-
tients remain at continual risk for the development of acute cel-
lular rejection (ACR), which involves injury to endomyocardial
tissue due to inﬂammatory cell inﬁltration and myocyte dam-
age that may be accompanied by graft dysfunction or failure
(Billingham et al., 1990; Subherwal et al., 2004; Stewart et al.,
2005). The incidence of ACR is highest in the immediate post-
transplant period and declines during the remainder of the ﬁrst
year and continually thereafter, but remains a clinical concern
even many years after transplantation (Figure 1) (Gradek et al.,
2001; Patel and Kobashigawa, 2006).
To diagnose ACR, transplant cardiologists perform transve-
nous biopsy of the right ventricular septum (Caves et al., 1973,
1974),whichyieldsspecimensthatcanbepathologicallygraded
using a scale ranging from normal tissue to severe injury
(Billingham et al., 1990; Stewart et al., 2005). The performance
of endomyocardial biopsies occurs either as part of surveillance
monitoring protocols with procedures scheduled at frequent in-
tervals during the ﬁrst post-transplant year and intermittently
thereafter, or when clinically indicated at any time. Several as-
pects of the biopsy procedure, including tissue sampling error,
invasiveness, patient discomfort, risk of morbidity (Hauck and
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FIG. 1. Time-dependent risk and incidence of acute cellular rejection in heart transplant recipients. The risk for acute cellular rejection (ACR) is highest
immediately post-operatively, declines during the remainder of the ﬁrst year, and remains an ongoing clinical concern.
Edwards, 1992; Baraldi-Junkins et al., 1993; Bhat et al., 1993;
Williams et al., 1996; Gradek et al., 2001), and variability in
biopsy interpretations (Nielsen et al., 1993; Winters and Mc-
Manus, 1996; Marboe et al., 2005), have prompted the develop-
mentofnon-invasivealternativestoenhanceimmunomonitoring
inhearttransplantpatients(Mehraetal.,2002;Subherwaletal.,
2004).
AlloMap
  R molecular expression testing for the management
of acute cellular rejection (ACR) in cardiac allograft recipi-
ents (Deng et al., 2006b) exempliﬁes the clinical utility of gene
expression technologies in heart transplant immunodiagnostics
and immunomonitoring (Horwitz et al., 2004; Schoels et al.,
2004). The administration of immunosuppressive regimens at-
tenuates the immune responses that cause acute and chronic
endomyocardial tissue injuries, but requires a delicate vigilance
to avoid the immediate and delayed morbidities of either ex-
cessive or inadequate therapy. Over-immunosuppression may
diminish immune responses and hinder defenses against infec-
tious pathogens or impair tumor surveillance mechanisms, and
may also contribute to the development of metabolic compli-
cations or end-organ toxicities. Under-immunosuppression en-
hances a patient’s risk for ACR and allograft dysfunction or
failure. By proﬁling the expression of a discrete cohort of genes
correlatingspeciﬁcallywithACR,theAlloMaptestoffersanal-
ternative, non-invasive approach for immunomonitoring based
ontheanalysisofcirculatingimmuneeffectorcellsinperipheral
blood samples of heart transplant patients (Deng et al., 2006b).
Quantitative measurements of intracellular mRNA levels in
peripheral blood mononuclear cells (PBMCs) using the real-
time polymerase chain reaction (rt-PCR) enables the AlloMap
test to distinguish dynamic changes in the expression of genes
correlating with the absence or presence of acute cellular rejec-
tion (ACR) (p = 0.0018) in cardiac allografts. The multi-gene
ACR classiﬁer provides molecular insights into a patient’s risk
for ACR by distilling the cumulative expression levels of its
informative genes into a single score on a scale of 0 to 40 by in-
corporating weighted, gene-speciﬁc coefﬁcients derived during
the classiﬁer’s development and then validated in the CARGO
Study (Deng et al., 2006b). The clinical utility of the AlloMap
test derives from its high negative predictive value (NPV), en-
abling it to guide clinicians in ruling out current ACR in the
context of the time elapsed since transplantation (time post-
transplant) (Deng et al., 2006b; Mehra et al., 2006). Although
the incidence of ACR is highest in the immediate peri-operative
period, rates decline during the ﬁrst year and thereafter (Eisen
etal.,2003;Klingenbergetal.,2003).However,ACRalsooccurs
in an episodic manner with variable or progressive severity that
necessitates diagnostic protocols that include both surveillance
and symptom-driven immunomonitoring (Mehra et al., 2002;
Patel and Kobashigawa, 2006). The inclusion of the AlloMap
test in such protocols may facilitate convenient and repetitive
diagnostic testing in cardiac transplant recipients as its perfor-
mancerequiresaperipheralbloodsampleratherthananinvasive
biopsy procedure.
Cardiac Allograft Pathology
Host immune responses to cardiac allografts induce inﬂam-
matory cell inﬁltration in the endomyocardium, resulting in a
spectrum of tissue injury that may be accompanied by myocyte
damage and dysfunction of the engrafted heart. Monitoring for
subclinical and clinically suspected episodes of ACR includes
routine history and physical examinations supplemented by se-
rialfunctionalassessmentsbyechocardiographyandhistopatho-
logic evaluations of endomyocardium sampled by transvenous
biopsy of the right ventricular septum. Patterns of cellular in-
ﬁltration and myocyte damage observed using light microscopy
enable pathologists to assign grades along a spectrum from nor-
mal endomyocardium to severe ACR using the 1990 (0, 1A, 1B,
2, 3A, 3B or 4) or 2004 (0R, 1R, 2R or 3R) systems approved
by the International Society of Heart and Lung Transplantation
(ISHLT)(Billinghametal.,1990;Stewartetal.,2005).Moderate
to severe grades of ACR (≥3A or ≥2R) deﬁne clinical thresh-
olds for augmented immunosuppression therapy (Kobashigawa
et al., 2006) to attenuate alloimmune responses with the goals
of minimizing tissue injury and preserving allograft function.
The limitations of tissue-based ACR diagnosis associated
with the invasive biopsy procedure include inadequate tissue
samples (due to heterogeneity of endomyocardial injury), ob-
scured histopathology (e.g., septal ﬁbrosis), venous access dif-
ﬁculties, and risks of morbidity such as tricuspid valve insuf-
ﬁciency, dysrhythmias or ventricular perforation (Hauck and
Edwards, 1992; Baraldi-Junkins et al., 1993; Bhat et al., 1993;
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interpretation of biopsy specimens may also yield diagnostic
uncertainty due to intra- and inter-reader variabilities (Nielsen
et al., 1993; Winters and McManus, 1996; Marboe et al., 2005)
and the occurrence of nodular endocardial inﬁltrates known as
Quilty lesions (Pardo-Mindan and Lozano, 1991; Joshi et al.,
1995; Marboe et al., 2005). Despite such limitations, endomy-
ocardial biopsies remain a familiar diagnostic tool that may be
complemented by new molecular insights provided by the Al-
loMap test.
AlloMap Genes
Genes comprising the AlloMap test have been implicated in
diverse immunoregulatory pathways in a variety of immune and
non-immune cells (Deng et al., 2006b; Zeevi et al., 2006). The
developmentoftheACRclassiﬁeremphasizedaninclusivestrat-
egywithcandidategenebiomarkersforACRidentiﬁedeitherby
implicationinmolecularpathwayssubstantiatedintheliterature
or through a discovery process utilizing leukocyte-speciﬁc gene
microarrays. The subsequent validation of these biomarkers us-
ing quantitative rt-PCR yielded a subgroup of genes individu-
ally correlating with the clinical endpoint of ACR. Included in
this subgroup were genes already implicated in a myriad of al-
loimmune responses detected by genomic methods in engrafted
tissues or other clinical specimens from both cardiac and non-
cardiac allograft recipients. However, the linear discriminant
analysis used to derive the classiﬁer identiﬁed a combination of
20 genes that best distinguished cardiac allograft ACR, with a
subgroupof11informativegenesthatdidnotincludemanypre-
FIG. 2. TheAlloMaptestscorereﬂectsdifferentialgeneexpressionindiverseregulatorypathways.TheAlloMaptestclassiﬁerforacutecellularrejection(ACR)
consists of 20 genes, including 11 that inform on a variety of regulatory pathways and contribute to its 7 terms, which correspond to the expression of individual
genes or the average expression levels of coordinately expressed genes termed metagenes. The classiﬁer also includes 9 genes used for normalization of gene
expression and quality control. Low AlloMap scores on a scale from 0 to 40, below the clinician-speciﬁed threshold, can be used to rule out ACR. Up-regulated
(gray) and down-regulated (black) expression of genes, as assayed in peripheral blood mononuclear cells (PBMCs) by qPCR, contributes to the AlloMap score.
viously identiﬁed in the literature (Deng et al., 2006a; Halloran
et al., 2006).
The remaining 9 AlloMap genes serve as control or refer-
ence genes used for test accuracy and reproducibility (Deng
et al., 2006b). The 11 informative genes correlating with ACR
are PDCD1, SEMA7A, RHOU, MARCH8 (MIR), WDR40,
ITGAM, IL1R2, FLT3, (C6orf25) G6B, PF4 and ITGA4,
suggesting transcriptional inﬂuences by T-cells, B-cells, neu-
trophils, platelets, and hematopoietic progenitor cells in a va-
riety of pathways regulating cell activation or homeostasis, in-
cluding 3 genes (IL1R2, ITGAM and FLT3) associated with
corticosteroid-sensitive mechanisms (Deng et al., 2006b).
AlloMap scores derived using the ACR classiﬁer reﬂect the
summationofallindividualcyclethreshold(Ct)valuesmeasured
by rt-PCR with relative weighting determined by each gene’s
accompanying coefﬁcient (Figure 2) (Deng et al., 2006b). The
inclusion of PDCD1 highlights its importance in T-cell stimula-
torypathwaysinmediatingACR,asothergenesalsoimplicated
insuchmechanismsdidnotdemonstratestatisticalperformance
orreproducibilitysufﬁcientfortheirinclusionintheassaypanel
(Deng et al., 2006a; Halloran et al., 2006). Both the molecular
mechanisms regulating these dynamic expression patterns and
theassociationsofthetest’sgeneswithhostresponsestocardiac
allografts remain an ongoing focus of investigation.
The issue of the physiologic relevance of individual gene
signatures is one of a number of concerns raised about the pro-
cessfordevelopingclinicallyusefulmolecularclassiﬁers.Addi-
tional concerns have focused on the applicability of statistically212 FANG
FIG. 3. Interpretation of the AlloMap test score depends on a clinically speciﬁed threshold. The clinician interprets the AlloMap score relative to a pre-selected
threshold on the 0-to-40 scale and the associated negative predictive value. A score below the threshold indicates a low risk for acute cellular rejection (ACR), thus
ruling out ACR. A score above the threshold suggests an increased risk for moderate-to-severe (≥3A/2R) ACR. By understanding the patient’s clinical course,
the time-dependent ACR risk, the clinical tolerance for false-negative or false-positive results, and practice-speciﬁc demographics, clinicians may personalize the
management of heart transplant patients through the selection of the AlloMap threshold.
signiﬁcant study results to the broad clinical population, the
validity of reference standards used as clinical endpoints (e.g.,
biopsy grades), and the balance between prioritizing the robust
performance of a multi-gene algorithm and the potential cost of
excluding a single gene previously shown to have mechanistic
relevance (Halloran et al., 2006). The development process of
the AlloMap test addressed many of these issues (Deng et al.,
2006a), which are clariﬁed in detail in this work. Ongoing re-
search in translational genomics will likely assuage many of
theseconcernsandrevealfurtherclinicalbeneﬁtsofthesynergy
ofintegratinggenomicinformation,clinicaldata,bioinformatics
andstatisticsinthedevelopmentofmoleculardiagnosticassays.
AlloMap Score Interpretation
Theclinicianassessesapatient’sACRriskbyinterpretingthe
AlloMap score relative to a pre-selected threshold value on the
0-to-40 scale and its associated NPV. Scores below the chosen
threshold indicate a low ACR risk, thus ruling out ACR, while
those above suggest an increased risk for ACR. Figure 3 illus-
tratesthedecisionanalysisfacedbytheclinicianintheselection
of a threshold for a given patient. Since the high NPV enables
an AlloMap score to rule out grade ≥3A rejection, the objective
is to choose a threshold value that enables an individual (below
threshold) AlloMap score to rule out grade ≥3A rejection (e.g.,
a true negative result), while minimizing the likelihood that an
above-threshold score might be associated with no ACR (i.e.,
a false positive result). Selecting progressively lower threshold
values(leftwardmovementofthethresholdbar)mayassurethat
an individual score result correlates with no ACR, however, at
the cost of an increased likelihood of a false positive result with
an above threshold score.
By contrast, choosing higher threshold values (rightward
movement of the threshold bar) may minimize the likelihood
of false positive results, but increases the likelihood that a grade
≥3Arejectionmaybepresentwithabelowthresholdscore(i.e.,
false negative result). As with all diagnostic tests, the clinician
must perform a preemptive risk-beneﬁt analysis that considers
the potential consequences of any false negative or positive re-
sult for a given patient’s clinical status.
Thetimepost-transplant(basedonthedateoftestingrelative
to the transplant date) guides selection of the threshold in each
of three time intervals (>2t o≥6 months, >6t o≥12 months, or
>12 months) that reﬂects the appropriate time-dependent risk
for ACR. The initiation of AlloMap testing in stable patients
at >2 months post-transplant is based on the rationale that the
post-operative clinical course of most patients becomes rela-
tively stable after 2 months. The NPV is the test performance
parameter that guides the interpretation of AlloMap scores in
each time period; based on the prevalence of ACR in a given
population,itindicatestheabilityofanegativetestresulttopre-
dict the absence of grade ≥3A ACR (true negative) in contrast
to instances when grade ≥3A ACR is actually present (false
negative) (Riegelman, 2005b). The time-dependent prevalence
of grade ≥3A ACR for patients enrolled in the CARGO Study
permittedthedeterminationofanNPVforeveryAlloMapscore
in each of the three time periods (Deng et al., 2006b).
Since the NPV indicates the percentage of test results that
correctly predicts the absence of grade ≥3A ACR, a high NPV
is desirable to rule out ACR. To highlight the importance of the
NPV, the following example illustrates the interpretation strat-
egy for an individual AlloMap score based on the selection of
34 as the threshold value for a patient evaluated at one year
post-transplant. For this threshold and time post-transplant, the
NPV of 99.2% indicates that 99.2% of all results lower than 34
willsuccessfullypredicttheabsenceofACR(truenegative).By
contrast, 0.8% of results below the threshold may yield a false
negative result, indicating that in 8 instances for every 1000 test
events a score below 34 may be associated with the presence ofCLINICAL UTILITIES OF GENE EXPRESSION PROFILING 213
ACR.Therefore,determiningthetimepost-transplantforthepa-
tientateachtestdateandconsideringtheNPVwithitsestimates
of true negative and false negative results both play important
roles in guiding the clinician in selecting the appropriate thresh-
old value.
Threshold Selection
The selection of a threshold value depends not only on the
time post-transplant, but also on the clinician’s knowledge of a
patient’s post-operative course and the prevailing practice envi-
ronment. Inherent in any test interpretation is the risk analysis
associatedwiththebalancingoffalsenegativeandfalsepositive
testresults.Afalsenegativeresultindicatesamisseddiagnosisof
a disease or condition, with the potential clinical consequences
determined by the magnitude of the associated morbidities or
sequelae. A false positive result may adversely inﬂuence clini-
cal decision-making by prompting an action such as treatment
or a procedure that is unnecessary given the true absence of the
diseaseorcondition(Riegelman,2005a).Theabilityofapatient
totolerateaclinicalactionbasedonafalsenegativeorfalsepos-
itive result depends on multiple factors, including the frequency
or prevalence of the disease, the current status, and the prior
course, with any clinical instability lowering the tolerance for
errant diagnoses. If the disease prevalence is relatively low or
a false negative result may be clinically tolerable, then a higher
AlloMap threshold may be appropriate.
Bycontrast,alowerAlloMapthresholdmaybeoptimalifthe
disease prevalence is comparatively high or if a false negative
result is likely to contribute to adverse outcomes. Factors af-
fecting threshold selection include not only the time-dependent
diseaseprevalence,butalsotheexperienceormanagementstyle
of clinicians and the distribution of patient risk proﬁles in a
givenpractice.Therefore,theconsiderationofapatient’scourse,
the disease prevalence, the clinical tolerance for false negative
or false positive results, and practice-speciﬁc demographics is
likely to guide the clinician’s approach to personalizing the care
ofahearttransplantpatientthroughtheselectionoftheAlloMap
threshold.
Clinical Experience with AlloMap Testing
Interpreting the AlloMap score initially in the context of
biopsy data enables clinicians to use their accrued experience
with pathology as they incorporatemolecular expression testing
into their management protocols. In the CARGO Study biopsy
grades served as a surrogate for alloimmune status in both the
development and veriﬁcation of the AlloMap test, and also en-
abled the derivation of its performance parameters based on the
observed agreement of their results (Deng et al., 2006b). How-
ever, disagreement between biopsy and AlloMap results, or dis-
cordance, is also expected as each approach uses different, but
complementary technologies to assess ACR.
An accurate biopsy grade requires the satisfaction of criteria
for tissue sample adequacy and tissue injury based on light mi-
croscopic criteria assessing inﬂammatory cell inﬁltration, my-
ocytedamage,andotherfeaturesdistortingnormalendomyocar-
dial architecture (Billingham et al., 1990; Stewart et al., 2005).
The AlloMap test score results from the quantiﬁcation of intra-
cellular mRNA levels of 20 genes, which in combination dif-
ferentiate the absence or presence of ACR in cardiac allografts
(Deng et al., 2006b). An initial multi-center experience with the
clinical adoption of AlloMap testing in conjunction with biopsy
proceduresillustratedfourscenariosinwhichtheresultsofboth
tests either demonstrate diagnostic agreement (concordance) or
disagreement (discordance).
The concurrent performance of endomyocardial biopsy and
AlloMap testing in 211 evaluations of patients at or beyond
1 year post-transplant enabled the calculation of agreement
or disagreement rates between negative (<3A/2R) or positive
(≥3A/2R) biopsy results and negative (below threshold) or pos-
itive (above threshold) AlloMap scores. An AlloMap score be-
low the threshold value of 34 accompanied a negative biopsy
resultin69.7%ofthetestevents,whileanabovethresholdscore
occurredwithall(n=5)positivebiopsies.Noinstancesofapos-
itivebiopsyoccurredwithabelowthresholdAlloMapscore.By
contrast, an above threshold AlloMap score (positive result) ac-
companied59biopsiesinterpretedasnegative(<3A/2R),yield-
ing a discordance rate of 28%. In this analysis using a threshold
value of 34 at 1 year post-transplant, the derived performance
parameters for the AlloMap test included an NPV of 100% and
a PPV of 7.8% (Starling et al., 2006). These data substantiate
those yielded by the CARGO Study and support the use of the
AlloMap test in ruling out ACR.
The expectation of discordance between biopsy grades and
AlloMap scores stems from an analysis of established and pos-
tulated factors that may inﬂuence the false negative or false
positive rates of their respective results. Interpretation of en-
domyocardial biopsies by a participating center’s pathologist
is the standard utilized to assess the clinical endpoint of ACR
in clinical studies, which may also require re-interpretation of
the original biopsies by a panel of study pathologists as part of
the study design (Nielsen et al., 1993; Winters and McManus,
1996; Marboe et al., 2005). The early demonstration of the abil-
ity of transvenous endomyocardial biopsy to obtain tissue to
assess ACR (Caves et al., 1973, 1974) led to the development of
consensus criteria for its interpretation to facilitate grading uni-
formity and communication, as stipulated in the original 1990
grading system that underwent revision in 2004.
Both grading systems emphasize the sufﬁciency of tissue
samplesforanalysisandtheneedtoadheretocriteriadelineating
the following: the focality or diffuseness of inﬂammatory cell
inﬁltration, any evidence of myocyte damage, the presence of
nodular endocardial inﬁltrates known as Quilty lesions, and ad-
ditionalmorphologiccriteriaassociatedwithantibody-mediated
rejection (AMR) (Billingham et al., 1990; Stewart et al., 2005).
Therefore,clinicallyindeterminatebiopsyresultsmayresultdue
to issues associated with either the procedure or tissue interpre-
tation. Sampling error may result from the acquisition of tissue214 FANG
that is of insufﬁcient quantity for analysis, not representative
of the heterogeneous injury, or obscured by scarring. Known
variabilities in endomyocardial biopsy interpretation may also
contribute to diagnostic uncertainty in both practice and inves-
tigational settings.
Endomyocardial Biopsy Interpretation
Both intra- and inter-reader variability of endomyocar-
dial biopsies occurs, due in part to potentially confound-
ing Quilty lesions, which has led to the requirement for
biopsy re-interpretation and grade re-assignments to enhance
the stringency of the clinico-pathologic ACR endpoint in stud-
ies (Nielsen et al., 1993; Winters and McManus, 1996; Deng
et al., 2006b). An analysis of pathology data in the CARGO
Study substantiated the known interpretive variability for biop-
sies and also demonstrated that individual pathologists may
favor the assignment of moderate to severe ACR grades. Of
all biopsies graded as ≥3A by study center pathologists, 40%
were conﬁrmed by a 3-member pathology panel, while the
best concordance for assigning ≥3A grades among the three
panel pathologists was 58% (Marboe et al., 2005). These biop-
sies with ≥3A grades conﬁrmed by the panel were used to
develop and validate the AlloMap test, with the calculation
of an NPV for each score based on the time-dependent ACR
prevalence.
TheAlloMaptesthasahighNPV,rangingfrom∼98to99%,
for scores considered as appropriate clinical threshold values
in each of the three time periods post-transplant (Deng et al.,
2006b).Inadditiontothemolecularandbioinformaticstrategies
used to derive the classiﬁer, the high NPV of the AlloMap test
also stems, in part, from the current lower prevalence of ACR
resulting from state-of-the-art immunosuppression and moni-
toring strategies (Eisen et al., 2003; Subherwal et al., 2004; Pa-
tel and Kobashigawa, 2006). The associated positive predictive
value(PPV)forindividualAlloMapscoresislessthan15%,due
mainly to the relatively low time-dependent prevalence of grade
≥3A ACR (Gradek et al., 2001; Subherwal et al., 2004), high-
lighting the ability of disease prevalence to limit a test’s PPV
(Riegelman, 2005b). Thus, while the AlloMap test may guide
clinician’s in ruling out ACR, it is limited in its ability to rule in
ACR.
Based on the hypothesis that genes in the ACR classiﬁer
may assess molecular pathways active in other alloimmune
processes, investigators have postulated that above threshold
AlloMap scores may also be manifestations of cardiac al-
lograft vasculopathy (CAV) (Yamani et al., 2005) or AMR
(Starling et al., 2006). In addition, the sensitivity of rt-PCR
for quantifying diverse intracellular genes in PBMCs also sug-
gests that the AlloMap test may assess early, systemic al-
loimmune responses that contribute to ACR prior to the de-
velopment of tissue manifestations that sufﬁce for detection
by light microscopy and satisfy the ISHLT grading system
criteria.
Negative Biopsy and Above-Threshold AlloMap Results
Discordance highlighted by a negative biopsy result and a
“high” (above threshold or positive) AlloMap score may be
clariﬁed by reviewing the diverse factors inﬂuencing the rela-
tive likelihood of either result being a false negative or false
positive. In the CARGO Study a biopsy assigned grades 0
(n = 416), 1A/1B (n = 174) or 2 (n = 159) by a study center
pathologist received conﬁrmation by the 3-member pathology
panel in 87%, 48% or 17% of cases, respectively; the agreement
of the 3-member panel on their own assignments of grades 0,
1A/1Bor2forthesebiopsieswas93%,71%or60%,respectively
(Marboe et al., 2005). The observed interpretive variability for
these grades that are used to deﬁne a negative biopsy (<3A)
suggests some diagnostic uncertainty and highlights the poten-
tial for a false negative biopsy result. Although above threshold
AlloMap scores suggest increased risk for ACR, investigators
have postulated that other factors may also yield “high” scores.
ThemaximumPPVofAlloMapthresholdvaluesrangesfrom
14.3% (>2t o≤6 months) to 9.9% (>12 months), demonstrat-
ing the inﬂuence of the diminishing time-dependent prevalence
of ACR and that all above threshold test scores do not indicate
an episode of ACR. Some investigators have hypothesized that
“high” AlloMap scores later post-transplant may be associated
with the development of CAV (Yamani et al., 2005). Data from
theCARGOStudyshowedthatabovethresholdAlloMapscores
may also represent grade 1B biopsies, as the mean score for this
subgroup of mild ACR is indistinguishable from that for grades
≥3A (Bernstein et al., 2005, 2007), which suggests the molecu-
larsimilarityofthesegrades.Thevalidationofthesehypotheses
and others postulating early sensitivity of the AlloMap test for
systemic alloimmune activation or AMR remain the focus of
ongoing investigations.
Thepotentialalsoexistsfordiscordancegeneratedbyaposi-
tive(≥3A/2R)biopsyresultanda“low”(belowthresholdorneg-
ative) AlloMap score. In addition to the known intra- and inter-
reader variability in interpreting ≥3A/2R results that can result
in false-positive biopsy results (Marboe et al., 2005), other data
suggest that some biopsies graded as ≥3A may resolve without
therapy (Klingenberg et al., 2003). An as yet unproven hypoth-
esis for a below threshold AlloMap score is that in this setting
it may reﬂect resolving systemic alloimmune activation prior to
the restoration of normal tissue architecture. Since the AlloMap
test does reﬂect a patient’s alloimmune status, an additional fac-
tor that may yield a lower than expected score is either intended
orunintendedaugmentationofsteroidimmunosuppressivether-
apy and its relationship to the timing of the acquisition of the
blood sample for testing.
The management of discordant clinical data often includes
an assessment of the certainty or robustness of the information
provided by a given diagnostic modality. Since the differen-
tial diagnosis for potentially discordant results between biopsy
grades and AlloMap scores is broad, avoiding (or minimiz-
ing) discordance might depend on enhancing the information
provided by biopsies or improving molecular understanding ofCLINICAL UTILITIES OF GENE EXPRESSION PROFILING 215
transplant-associated genomic responses. The revision of the
classiﬁcation system for acute cellular rejection represents one
collaborative effort between clinicians and pathologists to im-
prove the utility of the biopsy grades (Stewart et al., 2005).
The application of genomic technologies to clinical disorders
has been explosive and is likely to clarify further the molec-
ular mechanisms mediating recipient responses to cardiac al-
lografts. Additional genomic information may help clarify any
discordancethatmayariseincomparingtheresultsofmolecular
diagnostic assays to more traditional tests.
Potential Clinical Inﬂuences on AlloMap Score
Interpretation
Investigations of potentially confounding inﬂuences on the
AlloMapscoreanditsinterpretationhavefocusedonfactorsthat
directly or indirectly affect transplant-associated immunoregu-
latory pathways. During the early period after transplantation,
clinicians maintain a posture of vigilance for infection in the
setting of the diminishing effects of induction therapy and de-
creasing steroid immunosuppression. Although monoclonal or
polyclonal antibody therapeutics target circulating immune ef-
fector cells, an analysis of the CARGO Study data identiﬁed
neither an inﬂuence of induction therapy on the AlloMap score,
nor any signiﬁcant changes in the expression level of individual
constituent genes (Mehra et al., 2007).
The objective of minimizing corticosteroid side effects has
led to the practice of steroid withdrawal, with doses often de-
creased to below 20 mg daily by 1 to 2 months post-transplant
(Eisen et al., 2003; Rosenbaum et al., 2006). In this dose range,
corticosteroids do not inﬂuence the AlloMap score, but doses
exceeding 20 mg daily may alter the expression of three ACR
classiﬁer genes, including IL1R2, ITGAM and FLT3, that may
contributetoalowerAlloMapscore(Dengetal.,2006b;Starling
et al., 2006). Therefore, the usual practice of maintaining low
oral doses mitigates the effects of steroids on patient selection
for AlloMap testing. Although investigations of other immuno-
suppressive agents in the CARGO Study have not identiﬁed any
inﬂuences on the AlloMap test, their potential effects on gene
expression remain a focus of study.
A cost of immunosuppression is increased patient suscepti-
bility to opportunistic infections, and more frequent or severe
sequelae from bacterial infections (Fishman and Rubin, 1998).
The potential overlap between innate (infection-associated) and
adaptive (transplant-associated) immune responses in cardiac
allograft recipients has also engendered concerns about the po-
tential effects of infection on AlloMap test interpretation. Given
the clinical impact of cytomegalovirus (CMV) infection or dis-
ease (Zamora et al., 2005), an analysis of the CARGO Study
data investigated its inﬂuence on PBMC gene expression pro-
ﬁles and demonstrated that its peripheral molecular signature
did not overlap with genes comprising the AlloMap test; more-
over,theabsenceorpresenceofCMVinfectiondidnotinﬂuence
AlloMap test scores in patients with ACR (Deng et al., 2004).
To assess the broader inﬂuence of infection, the AlloMap genes
were compared to those identiﬁed in host responses to bacterial,
fungal and viral pathogens; these analyses did not reveal any
overlap between the ACR classiﬁer genes and those identiﬁed
in infection response pathways in various studies at the level
of cells, animal models, or clinical investigations (Jenner and
Young, 2005).
Based on the design of gene expression analyses in the
CARGO Study, the likelihood that either immunosuppression
therapy or infection might inﬂuence the AlloMap test interpre-
tation is also diminished by the inclusion of patients with these
clinical phenotypes in both the experimental and control groups
ofthestudiesperformed(Dengetal.,2004).Sincegeneproﬁling
analyses distinguish patterns of expression based on differences
in the clinical phenotypes of the patients, the inclusion of these
clinical inﬂuences in both study groups suggests that any poten-
tial inﬂuences on gene expression would be minimized.
AlloMap Testing and Clinical Protocols
The incorporation of the AlloMap test into management
protocols will enable clinicians to assess its utility and to an-
swer many questions raised by the technology and sensitivity of
molecular diagnostics. Issues of timing, frequency and efﬁcacy
already familiar to clinicians using other diagnostic tests will
also guide the adoption of the AlloMap test. Consideration of
these factors creates an opportunity to personalize a patient’s
care and optimize a transplant center’s clinical outcomes. A pa-
tient’scoursewithrespecttoACRepisodesguidesongoingdiag-
nostic monitoring and therapeutic management for individuals,
while the characterization of risk proﬁles identiﬁes patient sub-
groups requiring heightened attention and appropriate tailoring
of established practices.
Aswithalldiagnostictests,theinterpretationofanindividual
AlloMaptestresultisoptimalinalongitudinalfashion(Starling
et al., 2006) that permits interpretation of a current result in
the context of the patient’s clinical baseline to identify devia-
tions. The concurrent performance of endomyocardial biopsy
and AlloMap testing may be useful to establish an initial base-
line, which then enables interpretation of subsequent below or
abovethresholdscoresbycomparisontopriorscores,eitherwith
or without additional biopsy data. Information provided by the
history and physical examination, echocardiography and other
adjunctive diagnostic testing provide additional context, with
the objective insights supplied by AlloMap scores supplement-
ing the clinical acumen used in ACR risk assessments.
SUMMARY
AlloMap molecular expression testing is a clinical applica-
tion of gene expression proﬁling that enables a clinician to rule
outACRincardiacallograftrecipients.EachAlloMapthreshold
value has an associated NPV that guides a clinician in selecting
theappropriatethresholdforeachpatientinthreepost-transplant
periods, including >2t o≤6 months, >6t o≤12 months, and216 FANG
>12 months. An AlloMap score below the threshold rules out
ACR, while one above threshold suggests increased ACR risk.
Early clinical experience based on concurrent endomyocardial
biopsyandAlloMaptestingsubstantiatestheutilityofthetestin
rulingoutACRandalsohighlightsexpectationsoftestresultdis-
cordance, which occurs more commonly with a negative biopsy
and a “high” (above threshold or positive) AlloMap score.
The consideration of factors contributing to false negatives
or false positives will facilitate the interpretation of both tests’
results and subsequent decision analyses. The sensitivity of ge-
nomictechnologiesusedinthedevelopmentoftheAlloMaptest
andfuturemoleculardiagnostictestswilllikelyrequireacollab-
orativeapproachbetweenindustryandacademicinvestigatorsto
explore and answer the many provocative questions. Incorpora-
tion of the AlloMap test into management protocols will enable
clinicians not only to assess its clinical utility further, but also
to deﬁne its role in strategies optimizing the clinical outcomes
for heart transplant patients.
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